| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Pain and Neurosensory Mechanisms Branch, National Institute of Dental Research (Drs. Nelson, Park, and Max), the Clinical Center Nursing Department (Ms. Robinovitz), and the Developmental Endocrinology Branch, National Institute of Child Health and Development (Dr. Tsigos), National Institutes of Health, Bethesda, MD.
N-methyl-D-aspartate (NMDA) receptor antagonists relieve neuropathic pain in animal models, but side effects of dissociative anesthetic channel blockers, such as ketamine, have discouraged clinical application. Based on the hypothesis that low-affinity NMDA channel blockers might have a better therapeutic ratio, we carried out two randomized, double-blind, crossover trials comparing six weeks of oral dextromethorphan to placebo in two groups, made up of 14 patients with painful distal symmetrical diabetic neuropathy and 18 with postherpetic neuralgia. Thirteen patients with each diagnosis completed the comparison. Dosage was titrated in each patient to the highest level reached without disrupting normal activities; mean doses were 381 mglday in diabetics and 439 mglday in postherpetic neuralgia patients. In diabetic neuropathy, dextromethorphan decreased pain by a mean of 24% (95% CI: 6% to 42%, p = 0.011, relative to placebo. In postherpetic neuralgia, dextromethorphan did not reduce pain (95% CI: 10% decrease in pain to 14% increase in pain, p = 0.72). Five of 31 patients who took dextromethorphan dropped out due to sedation or ataxia during dose escalation, but the remaining patients all reached a reasonably well-tolerated maintenance dose. We conclude that dextromethorphan or other low-affinity NMDA channel blockers may have promise in the treatment of painful diabetic neuropathy.
This article has been cited by other articles:
|
|
 |
|
  L. L. Krypel Fibromyalgia: A Review of Its Pathophysiology and Drug Treatment Journal of Pharmacy Practice, February 1, 2009; 22(1): 6 - 16. [Abstract] [PDF]
|
|
|
|
 |
|
 C. E. Argoff, M.-M. Backonja, M. J. Belgrade, G. J. Bennett, M. R. Clark, B. E. Cole, D. A. Fishbain, G. A. Irving, B. H. McCarberg, and M. J. McLean Consensus Guidelines: Treatment Planning and Options Mayo Clin. Proc., April 1, 2006; 81(4_Suppl): S12 - S25. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Rowbotham Mechanisms of neuropathic pain and their implications for the design of clinical trials Neurology, December 29, 2005; 65(12_suppl_4): S66 - S73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Cohen, A. S. Chang, T. Larkin, and J. Mao The Intravenous Ketamine Test: A Predictive Response Tool for Oral Dextromethorphan Treatment in Neuropathic Pain Anesth. Analg., December 1, 2004; 99(6): 1753 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chen, T. J. Lamer, R. H. Rho, K. A. Marshall, B. T. Sitzman, S. M. Ghazi, and R. P. Brewer Contemporary Management of Neuropathic Pain for the Primary Care Physician Mayo Clin. Proc., December 1, 2004; 79(12): 1533 - 1545. [Abstract] [PDF]
|
|
|
|
|
|
R. M. Dubinsky, H. Kabbani, Z. El-Chami, C. Boutwell, and H. Ali Practice Parameter: Treatment of postherpetic neuralgia: An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, September 28, 2004; 63(6): 959 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Weinbroum, B. Bender, A. Nirkin, S. Chazan, I. Meller, and Y. Kollender Dextromethorphan-Associated Epidural Patient-Controlled Analgesia Provides Better Pain- and Analgesics-Sparing Effects than Dextromethorphan-Associated Intravenous Patient-Controlled Analgesia After Bone-Malignancy Resection: A Randomized, Placebo-Controlled, Double-Blinded Study Anesth. Analg., March 1, 2004; 98(3): 714 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-R. Chen and H.-L. Pan Up-Regulation of Spinal Muscarinic Receptors and Increased Antinociceptive Effect of Intrathecal Muscarine in Diabetic Rats J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 676 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tarral, P. Dostert, Y. Guillevic, L. Fabbri, I. Rondelli, F. Mariotti, and B. P. Imbimbo Safety, Pharmacokinetics, and Pharmacodynamics of CHF 3381, a Novel N-Methyl-D-Aspartate Antagonist, after Single Oral Doses in Healthy Subjects J. Clin. Pharmacol., August 1, 2003; 43(8): 901 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Mendell and Z. Sahenk Painful Sensory Neuropathy N. Engl. J. Med., March 27, 2003; 348(13): 1243 - 1255. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Wallace, M. C. Rowbotham, N. P. Katz, R. H. Dworkin, R. M. Dotson, B. S. Galer, R. L. Rauck, M. M. Backonja, S. N. Quessy, and P. D. Meisner A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain Neurology, December 10, 2002; 59(11): 1694 - 1700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Allen, A. L. Granger, and L. A. Dykstra Dextromethorphan Potentiates the Antinociceptive Effects of Morphine and the delta -Opioid Agonist SNC80 in Squirrel Monkeys J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Harden Complex regional pain syndrome Br. J. Anaesth., July 1, 2001; 87(1): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Allen and L. A. Dykstra N-Methyl-D-Aspartate Receptor Antagonists Potentiate the Antinociceptive Effects of Morphine in Squirrel Monkeys J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 288 - 297. [Abstract] [Full Text]
|
|
|
|
|
|
S. H. Sindrup and T. S. Jensen Pharmacologic treatment of pain in polyneuropathy Neurology, October 10, 2000; 55(7): 915 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Gilron, S. L. Booher, J. S. Rowan, B. Smoller, and M. B. Max A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias Neurology, October 10, 2000; 55(7): 964 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Nikolajsen, H. Gottrup, A. G. D. Kristensen, and T. S. Jensen Memantine (a N-Methyl-D-Aspartate Receptor Antagonist) in the Treatment of Neuropathic Pain After Amputation or Surgery: A Randomized, Double-Blinded, Cross-Over Study Anesth. Analg., October 1, 2000; 91(4): 960 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Fairbanks, K. L. Schreiber, K. L. Brewer, C.-G. Yu, L. S. Stone, K. F. Kitto, H. O. Nguyen, B. M. Grocholski, D. W. Shoeman, L. J. Kehl, et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury PNAS, September 12, 2000; 97(19): 10584 - 10589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Y. Chia, K. Liu, L.-H. Chow, and T.-Y. Lee The Preoperative Administration of Intravenous Dextromethorphan Reduces Postoperative Morphine Consumption Anesth. Analg., September 1, 1999; 89(3): 748 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-T. Wu, J.-C. Yu, C.-C. Yeh, S.-T. Liu, C.-Y. Li, S.-T. Ho, and C.-S. Wong Preincisional Dextromethorphan Treatment Decreases Postoperative Pain and Opioid Requirement After Laparoscopic Cholecystectomy Anesth. Analg., June 1, 1999; 88(6): 1331 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Rose, R. Cuy, D. E. Cohen, and M. S. Schreiner Preoperative Oral Dextromethorphan Does Not Reduce Pain or Analgesic Consumption in Children After Adenotonsillectomy Anesth. Analg., April 1, 1999; 88(4): 749 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Desmeules, M. K. Oestreicher, V. Piguet, A.-F. Allaz, and P. Dayer Contribution of Cytochrome P-4502D6 Phenotype to the Neuromodulatory Effects of Dextromethorphan J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 607 - 612. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. A. Low and R. M. Dotson Symptomatic Treatment of Painful Neuropathy JAMA, December 2, 1998; 280(21): 1863 - 1864. [Full Text] [PDF]
|
|
|
|
|
|
V. L. Metman, D. P. Dotto, R. Natte, P. van den Munckhof, and T. N. Chase Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease Neurology, July 1, 1998; 51(1): 203 - 206. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
